Comorbidities | | |
Malignant tumour | 1.61 (0.43–6.00) | 0.478 |
Chronic cardiopulmonary disease | 1.70 (0.60–4.84) | 0.321 |
Diabetes mellitus | 3.26 (1.10–9.62) | 0.033 |
Renal insufficiency | 2.48 (0.87–7.10) | 0.091 |
Symptoms and clinical status on admission | | |
Syncope | 1.93 (0.51–7.25) | 0.330 |
Hypoxia | 3.85 (1.28–11.60) | 0.017 |
Tachycardia | 3.76 (1.29–10.95) | 0.015 |
Mild hypotension | 2.08 (0.43–9.99) | 0.360 |
RV dysfunction on echocardiography or MDCT | 2.91 (0.90–9.38) | 0.074 |
Laboratory biomarkers | | |
hsTnT ≥14 pg·mL−1 | OR not calculable |
NT-proBNP ≥600 pg·mL−1 | OR not calculable |
Copeptin ≥24 pmol·L−1 | 5.44 (1.68–17.58) | 0.005 |
Copeptin ≥24 pmol·L−1 and hsTnT ≥14 pg·mL−1 and NT-proBNP ≥600 pg·mL−1 | 13.00 (3.91–42.72) | <0.001 |
Risk assessment models | | |
ESC 2014 algorithm (intermediate–high risk versus low risk/intermediate–low risk) | 4.66 (1.54–14.09) | 0.006 |
Bova score (intermediate–high risk versus low risk/intermediate–low risk) | 2.73 (0.89–8.42) | 0.080 |